Skip to main content

Investigational New Drugs

Ausgabe 4/2012

Inhalt (64 Artikel)

PRECLINICAL STUDIES

The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis

Christopher M. Cabello, Sarah D. Lamore, Warner B. Bair III, Shuxi Qiao, Sara Azimian, Jessica L. Lesson, Georg T. Wondrak

PRECLINICAL STUDIES

Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells

Zahid M. Delwar, Dimitrios Avramidis, Elna Follin, Yan Hua, Åke Siden, Mabel Cruz, Kajsa M. Paulsson, Juan Sebastian Yakisich

PRECLINICAL STUDIES

Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest

Won Ki Kim, Ju-Hwa Kim, Kyungsil Yoon, Sunshin Kim, Jungsil Ro, Han Sung Kang, Sungpil Yoon

PRECLINICAL STUDIES

Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models

Angela Maria Di Francesco, Paolo Ubezio, Anna Rita Torella, Daniela Meco, Filomena Pierri, Giuseppe Barone, Gabriella Cusano, Claudio Pisano, Maurizio D’Incalci, Riccardo Riccardi

PRECLINICAL STUDIES

Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.

Mohammad Abolhassani, Adeline Guais, Edward Sanders, Frédéric Campion, Iduna Fichtner, Jacques Bonte, Gianfranco Baronzio, Giammaria Fiorentini, Maurice Israël, Laurent Schwartz

PRECLINICAL STUDIES

Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-Methylfunicone from Penicillium pinophilum and cisplatin

Elisabetta Buommino, Anna De Filippis, Rosario Nicoletti, Massimo Menegozzo, Simona Menegozzo, Maria Letizia Ciavatta, Antonietta Rizzo, Virginia Brancato, Maria Antonietta Tufano, Giovanna Donnarumma

PRECLINICAL STUDIES

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

Yu Kataoka, Toru Mukohara, Hideo Tomioka, Yohei Funakoshi, Naomi Kiyota, Yutaka Fujiwara, Masakazu Yashiro, Kosei Hirakawa, Midori Hirai, Hironobu Minami

PRECLINICAL STUDIES

Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia

Darya Habibi, Nadya Ogloff, Reza B. Jalili, Arla Yost, Andrew P. Weng, Aziz Ghahary, Christopher J. Ong

PRECLINICAL STUDIES

The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma

Juliana Romanini, Tânia R. Mielcke, Paulo C. Leal, Cláudia P. Figueiredo, João B. Calixto, Fernanda B. Morrone, Eraldo L. Batista Jr, Maria M. Campos

PRECLINICAL STUDIES

Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor

Lih-Ching Hsu, David E. Durrant, Ching-Chun Huang, Nai-Wen Chi, Riccardo Baruchello, Riccardo Rondanin, Cinzia Rullo, Paolo Marchetti, Giuseppina Grisolia, Daniele Simoni, Ray M. Lee

PRECLINICAL STUDIES

The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells

Ansgar Brüning, Petra Burger, Andrea Gingelmaier, Ioannis Mylonas

PRECLINICAL STUDIES

In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors

Martin Schmidt-Hieber, Robert Dabrowski, Babette Aicher, Philipp Lohneis, Antonia Busse, Carola Tietze-Buerger, Birgit Reufi, Eckhard Thiel, Igor Wolfgang Blau

PRECLINICAL STUDIES

Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer

Jinah Park, Eunju Park, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Woo-Ho Kim, Do-Youn Oh, Yung-Jue Bang

PRECLINICAL STUDIES

Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis

James L. Figarola, Yehua Weng, Christopher Lincoln, David Horne, Samuel Rahbar

PRECLINICAL STUDIES

Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo

Juan R. Rodrigues, Jaime Charris, Rosa Ferrer, Neira Gamboa, Jorge Ángel, Bianca Nitzsche, Michael Hoepfner, Michael Lein, Klaus Jung, Claudia Abramjuk

PRECLINICAL STUDIES

A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL

Jung Jin Hwang, Yong Sook Kim, Taelim Kim, Mi Joung Kim, In Gab Jeong, Je-Hwan Lee, Jene Choi, Sejin Jang, Seonggu Ro, Choung-Soo Kim

PRECLINICAL STUDIES

Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis

Ahmad Raza, Blake A. Jacobson, Adam Benoit, Manish R. Patel, Joe Jay-Dixon, Hiroshi Hiasa, David M. Ferguson, Robert Arthur Kratzke

PRECLINICAL STUDIES

Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines

Timothy C. Horan, Michael A. Zompa, Christopher T. Seto, Kyu Kwang Kim, Richard G. Moore, Thilo S. Lange

PRECLINICAL STUDIES

Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death

Agata M. Wasik, Michael N. Gandy, Matthew McIldowie, Michelle J. Holder, Anita Chamba, Anita Challa, Katie D. Lewis, Stephen P. Young, Dagmar Scheel-Toellner, Martin J. Dyer, Nicholas M. Barnes, Matthew J. Piggott, John Gordon

PRECLINICAL STUDIES

Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines

Stefania Giudice, Luisa Benassi, Giorgia Bertazzoni, Eugenia Veratti, Daria Morini, Paola Azzoni, Maria P. Costi, Alberto Venturelli, Silvia Pirondi, Stefania Seidenari, Cristina Magnoni

PHASE I STUDIES

Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer

Taroh Satoh, Kensei Yamaguchi, Narikazu Boku, Wataru Okamoto, Tomotaka Shimamura, Kentaro Yamazaki, Xiaojin Shi, Hideyuki Mishima

Open Access PHASE I STUDIES

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

Ron J. Keizer, Anthe S. Zandvliet, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema

PHASE I STUDIES

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

Jean-Philippe Spano, Malcolm J. Moore, Yazdi K. Pithavala, Alejandro D. Ricart, Sinil Kim, Olivier Rixe

PHASE I STUDIES

Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma

Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Jongtae Lee, Dong-Seok Yim, Ho Yeong Lim

Open Access PHASE I STUDIES

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

Yasushi Goto, Ikuo Sekine, Maki Tanioka, Takashi Shibata, Chiharu Tanai, Hajime Asahina, Hiroshi Nokihara, Noboru Yamamoto, Hideo Kunitoh, Yuichiro Ohe, Hironori Kikkawa, Emiko Ohki, Tomohide Tamura

Open Access PHASE I STUDIES

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

Maarten J. Deenen, Heinz-Josef Klümpen, Dick J. Richel, Rolf W. Sparidans, Mariette J. Weterman, Jos H. Beijnen, Jan H. M. Schellens, Johanna W. Wilmink

PHASE I STUDIES

A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors

Elisabeth I. Heath, Karen Forman, Lisa Malburg, Shelby Gainer, A. Benjamin Suttle, Laurel Adams, Howard Ball, Patricia LoRusso

PHASE I STUDIES

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

Athanassios Argiris, Trevor M. Feinstein, Lin Wang, Tianbing Yang, Shruti Agrawal, Leonard J. Appleman, Ronald G. Stoller, Jennifer R. Grandis, Ann Marie Egloff

PHASE I STUDIES

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

Ramesh K. Ramanathan, Joe J. Stephenson, Glen J. Weiss, Linda A. Pestano, Ann Lowe, Alton Hiscox, Rafael A. Leos, Julie C. Martin, Lynn Kirkpatrick, Donald A. Richards

PHASE II STUDIES

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Andrew H. Ko, Hagop Youssoufian, Jayne Gurtler, Karel Dicke, Omar Kayaleh, Heinz-Josef Lenz, Mark Keaton, Terry Katz, Shaila Ballal, Eric K. Rowinsky

PHASE II STUDIES

Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status

Myoung Joo Kang, Yong Sang Hong, Kyu-pyo Kim, Sun Young Kim, Ji Yeon Baek, Min-Hee Ryu, Jae-Lyun Lee, Heung Moon Chang, Mi-Jung Kim, Hee Jin Chang, Yoon-Koo Kang, Tae Won Kim

PHASE II STUDIES

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

Jason E. Faris, Jamie Arnott, Hui Zheng, David P. Ryan, Thomas A. Abrams, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Peter C. Enzinger, Aram F. Hezel, Kimmie Ng, Brian M. Wolpin, Eunice L. Kwak

PHASE II STUDIES

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

Ken Kato, Keisho Chin, Takaki Yoshikawa, Kensei Yamaguchi, Yasushi Tsuji, Taito Esaki, Kenji Sakai, Masami Kimura, Tetsuya Hamaguchi, Yasuhiro Shimada, Yasuhiro Matsumura, Ryuji Ikeda

PHASE II STUDIES

Feasibility and effectiveness of inhaled carboplatin in NSCLC patients

Paul Zarogoulidis, Ellada Eleftheriadou, Iordanis Sapardanis, Vasiliki Zarogoulidou, Helliel Lithoxopoulou, Theodoros Kontakiotis, Nikolaos Karamanos, George Zachariadis, Maria Mabroudi, Athanasios Zisimopoulos, Kostantinos Zarogoulidis

PHASE II STUDIES

Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil

Valerie Florin, Eve Desmedt, Sophie Vercambre-Darras, Laurent Mortier

PHASE II STUDIES

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

Anthony B. El-Khoueiry, Cathryn J. Rankin, Edgar Ben-Josef, Heinz-Josef Lenz, Philip J. Gold, R. Darryl Hamilton, Rangaswamy Govindarajan, Cathy Eng, Charles D. Blanke

PHASE II STUDIES

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer

Emma K. Beardsley, Sebastien J. Hotte, Scott North, Susan L. Ellard, Eric Winquist, Christian Kollmannsberger, Som D. Mukherjee, Kim N. Chi

PHASE II STUDIES

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma

Wayne L. Furman, Lisa M. McGregor, M. Beth McCarville, Mihaela Onciu, Andrew M. Davidoff, Sandy Kovach, Dana Hawkins, Valerie McPherson, Peter J. Houghton, Catherine A. Billups, Jianrong Wu, Clinton F. Stewart, Victor M. Santana

PHASE II STUDIES

Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer

Byung Woog Kang, Jong Gwang Kim, Yee Soo Chae, Yoo Jin Lee, Soo Jung Lee, Joon Ho Moon, Sang Kyun Sohn, Min Kyu Jung, Seong Woo Jeon, Yun-Jin Jang, Jongduk Seo, Yong Hyun Lee, Ohkyung Kwon, Ho Young Chung, Wansik Yu

PHASE II STUDIES

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors

J. Paul Monk, Miguel Villalona-Calero, Joe Larkin, Greg Otterson, David S. Spriggs, Alison L. Hannah, Gillian F. Cropp, Robert G. Johnson, Martee L. Hensley

PHASE II STUDIES

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

David J. Adelstein, Cristina P. Rodriguez, Lisa A. Rybicki, Denise I. Ives, Thomas W. Rice

PHASE II STUDIES

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

Yasuhide Yamada, Tatsuro Yamaguchi, Hiroshi Matsumoto, Yasushi Ichikawa, Ayumu Goto, Ken Kato, Tetsuya Hamaguchi, Yasuhiro Shimada

SHORT REPORT

Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis

Annie Brion, Faezeh Legrand, Fabrice Larosa, Françoise Schillinger, Francine Garnache-Ottou, Philippe Helias, Jean Fontan, Marian Heczko, Philippe Delaby, Etienne Daguindau, Jacqueline Vuillier, Adrien Chauchet, Eric Deconinck

SHORT REPORT

Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure

Changhoon Yoo, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, Heung-Moon Chang, Jae-Lyun Lee, Tae Won Kim, Yoon-Koo Kang

SHORT REPORT

Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines

Yakini Brandy, Innocent Ononiwu, Dolapo Adedeji, Vonetta Williams, Claudia Mouamba, Yasmine Kanaan, Robert L. Copeland Jr, Dwayne A. Wright, Ray J. Butcher, Samuel R. Denmeade, Oladapo Bakare

SHORT REPORT

Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes

Joanna Edyta Fraczek, Mathieu Vinken, Dirk Tourwé, Tamara Vanhaecke, Vera Rogiers

SHORT REPORT

First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study

Veronica Marchetti, Mario Giorgi, Anna Fioravanti, Riccardo Finotello, Simonetta Citi, Bastianina Canu, Paola Orlandi, Teresa Di Desidero, Romano Danesi, Guido Bocci

SHORT REPORT

Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells

Erika Rimondi, Maria Grazia di Iasio, Arianna Gonelli, Claudio Celeghini, Paola Secchiero, Giorgio Zauli

SHORT REPORT

Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells

David Davidson, Jeremy Grenier, Veronica Martinez-Marignac, Lilian Amrein, May Shawi, Marc Tokars, Raquel Aloyz, Lawrence Panasci

SHORT REPORT

Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients

Olivier Mir, Jérôme Alexandre, Romain Coriat, Stanislas Ropert, Pascaline Boudou-Rouquette, Thach Bui, Jeanne Chapron, Jean-Philippe Durand, Daniel Dusser, François Goldwasser

SHORT REPORT

Reversible posterior leukoencephalopathy syndrome and trastuzumab

Hiroyasu Kaneda, Isamu Okamoto, Taroh Satoh, Kazuhiko Nakagawa

SHORT REPORT

Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma

Hee Kyung Ahn, Soohyeon Lee, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim

REVIEW

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

Yevgeniy Balagula, Shenhong Wu, Xiao Su, Darren R. Feldman, Mario E. Lacouture

REVIEW

Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies

Caroline Peyrode, Valérie Weber, Emmanuelle David, Aurélien Vidal, Philippe Auzeloux, Yves Communal, Marie Mélanie Dauplat, Sophie Besse, François Gouin, Dominique Heymann, Jean Michel Chezal, François Rédini, Elisabeth Miot-Noirault

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.